The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura), has received a 2024 Innovation Award from The Analytical Scientist1 for its live cell metabolic analyzer, LiCellMoTM. LiCellMo, launched for research use in Japan in September and the United States, UK, EU, China and other Asian select geographies in October2.
Stock up your family's medicine cabinet this Black Friday and Cyber Monday. WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing in preparation for the year-end holidays.
Nevro Corp. a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system. The CE marking allows Nevro to market HFX iQ in all countries that recognize this certification.
TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies, innovations, and achievements in the global fight to end TB. The full-day session will bring together a distinguished group of global stakeholders dedicated to addressing and eliminating the TB pandemic.
Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, delivers life science companies industry-specific data orchestration with TrinityEDGE, Commercial Data Foundations.
Traditionally, kidney health has been monitored by measuring blood creatinine levels, which indicate muscle breakdown. High creatinine levels can suggest that the kidneys are not filtering waste efficiently. However, creatinine levels can be affected by a person's muscle mass and only rise significantly after more than 75% of kidney function is lost.
A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) – a rare genetic bleeding condition that causes enlargements and tangles of veins and arteries, as well as other malformations of the blood vessels – according to new research from The Feinstein Institutes for Medical Research.
As people live longer than ever before, the incidence of aging-related, chronic diseases is on the rise, severely impacting quality of life and placing an unprecedented financial and care burden on overwhelmed families, government agencies and healthcare providers.
Akadeum Life Sciences is excited to announce its participation Mesa, a globally recognized program held at the iconic Arizona Biltmore. This premier program brings together senior executives and key decision-makers from the cell and gene therapy industry to engage in critical discussions, presentations, and partnering sessions aimed at advancing the next generation of therapeutics.
To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scientific Inc. is expanding its oral solid dose (OSD) footprint with a $22-million total investment since 2021 in its Cincinnati, Ohio, and Bend, Ore. sites.